Table 1.
Suggested therapy for RVIs in transplant and oncology patients
| Respiratory Virus | Diagnosis | Isolation Precautions1 | Suggested Management |
|---|---|---|---|
| Influenza | DFA, NAT, serology, culture | Droplet Airborne for pandemic strains |
Oseltamivir, 75–150 mg po bid × 5–10 d Zanamivir, 2 puffs bid × 5 d Amantadine, 100 mg bid Rimantadine, 100 mg bid |
| RSV | DFA, NAT | Droplet and contact | Ribavirin IVIg or RSV-Ig Palivizumab |
| Parainfluenza | DFA, NAT | Droplet | Ribavirin (aerosolized, po, IV) |
| Adenovirus | DFA, NAT | Droplet | Cidofovir, 3 mg/kg IV once weekly Ribavirin? IVIG |
| Coronavirus | NAT | Droplet Airborne for SARS-CoV |
Supportive care Ribavirin (for SARS-CoV) |
| Human metapneumovirus | NAT | Droplet | Ribavirin? Supportive care |
| Rhinovirus | NAT | Droplet | Supportive care |
| Parvovirus B19 | NAT, serology | Droplet | IVIG |
| Bocavirus | NAT | Droplet | Supportive care |
| WU/KI viruses | NAT | Droplet | Supportive care |
Not all diagnostic tests are available in all clinical laboratories. Some diagnostic tests are primarily used for research purposes.
Doses of antivirals are standard doses for adults with normal creatinine clearance.
Abbreviations: DFA, direct fluorescent antibody; IVIG, intravenous immunoglobin; NAT, nucleic acid amplification testing; RSV, respiratory syncytial virus; SARS-CoV, severe acute respiratory syndrome associated coronavirus.